{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T23:02:17Z","timestamp":1769727737177,"version":"3.49.0"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100008087","name":"Guthy-Jackson Charitable Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008087","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000890","name":"National Multiple Sclerosis Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000890","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006314","name":"Biogen Idec","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006314","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004755","name":"Serono","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004755","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004329","name":"Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jns-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.jns.2018.01.042","type":"journal-article","created":{"date-parts":[[2018,2,2]],"date-time":"2018-02-02T08:24:15Z","timestamp":1517559855000},"page":"170-173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Anti-myelin oligodendrocyte glycoprotein (MOG) antibodies in patients with optic neuritis and seizures"],"prefix":"10.1016","volume":"387","author":[{"given":"Josef Maxwell","family":"Gutman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Kupersmith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Galetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilya","family":"Kister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2018.01.042_bb0005","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.autrev.2015.12.004","article-title":"Anti-MOG antibody: the history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination","volume":"15","author":"Ramanathan","year":"2016","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jns.2018.01.042_bb0010","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1136\/jnnp-2014-308346","article-title":"Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein","volume":"86","author":"Baumann","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2018.01.042_bb0015","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1212\/WNL.0000000000004117","article-title":"Diagnostic algorithm for relapsing acquired demyelinating syndromes in children","volume":"89","author":"Hacohen","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2018.01.042_bb0020","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000131","article-title":"Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis","volume":"2","author":"Chalmoukou","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflammation"},{"key":"10.1016\/j.jns.2018.01.042_bb0025","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","article-title":"In cooperation with the N.O.S.G. (nemos), MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.jns.2018.01.042_bb0030","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000322","article-title":"MOG antibody\u2013positive, benign, unilateral, cerebral cortical encephalitis with epilepsy","volume":"4","author":"Ogawa","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflammation"},{"key":"10.1016\/j.jns.2018.01.042_bb0035","article-title":"Seizures and encephalitis in myelin oligodendrocyte glycoprotein IgG disease vs aquaporin 4 IgG disease","author":"Hamid","year":"2017","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jns.2018.01.042_bb0040","doi-asserted-by":"crossref","first-page":"e231","DOI":"10.1212\/WNL.0000000000004628","article-title":"Clinical reasoning: a patient with a history of encephalomyelitis and recurrent optic neuritis","volume":"89","author":"Gutman","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2018.01.042_bb0045","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.braindev.2014.02.002","article-title":"Anti-myelin oligodendrocyte glycoprotein (MOG) antibodies in a Japanese boy with recurrent optic neuritis","volume":"37","author":"Tsuburaya","year":"2015","journal-title":"Brain and Development"},{"key":"10.1016\/j.jns.2018.01.042_bb0050","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/brain\/awg045","article-title":"Chronic relapsing inflammatory optic neuropathy (CRION)","volume":"126","author":"Kidd","year":"2003","journal-title":"Brain"},{"key":"10.1016\/j.jns.2018.01.042_bb0055","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000040","article-title":"Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis","volume":"1","author":"Ramanathan","year":"2014","journal-title":"Neurol. Neuroimmunol. Neuroinflammation"},{"key":"10.1016\/j.jns.2018.01.042_bb0060","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1177\/1352458512466317","article-title":"Acute disseminated encephalomyelitis followed by recurrent or monophasic optic neuritis in pediatric patients","volume":"19","author":"Huppke","year":"2012","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.jns.2018.01.042_bb0065","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1177\/1352458516631038","article-title":"Children with multiphasic disseminated encephalomyelitis and antibodies to the myelin oligodendrocyte glycoprotein (MOG): extending the spectrum of MOG antibody positive diseases","volume":"22","author":"Baumann","year":"2016","journal-title":"Mult. Scler. J."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X18300583?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X18300583?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,4,4]],"date-time":"2021-04-04T23:28:01Z","timestamp":1617578881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X18300583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":13,"alternative-id":["S0022510X18300583"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2018.01.042","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-myelin oligodendrocyte glycoprotein (MOG) antibodies in patients with optic neuritis and seizures","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2018.01.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}